Navigation Links
CBLPath Opens Manhattan Facility
Date:5/28/2009

New location brings laboratory services closer to Metropolitan area physicians

Rye Brook, N.Y. (PRWEB) May 28, 2009 -- CBLPath, Inc., one of the nation's fastest-growing providers of specialized anatomic pathology services, today announced the opening of its Manhattan Facility as part of the company's continuous effort to enhance services for Metropolitan area physicians. Licensed by the New York State Department of Health (NYSDOH), the new facility is located at 400 East 66th Street, Suite 2D, and augments CBLPath's state-of-the-industry 66,000-square-foot main laboratory facility, which is located at 760 Westchester Avenue in Rye Brook, N.Y.

"We're very pleased to be able to bring our laboratory services closer to our physician-clients' practices," said Madeline Vazquez, M.D., Associate Director of the Manhattan Facility.

To find out more about the CBLPath Manhattan Facility, contact the company's Client Services Department or your local sales and service representative at 877.CBLPath (877.225.7284).

CBLPath, Inc. is a landmark anatomic pathology laboratory that delivers state-of-the-industry diagnostic testing and innovative technology solutions to its physician-clients across the nation. Founded in 1988 as Cytopath Biopsy Lab, CBLPath quickly established a reputation for providing timely and highly accurate diagnoses along with extraordinary customer service and a true patient-centered commitment. Additional information about the company is available by visiting CBLPath.com.

This news release may contain forward-looking statements (as delineated in the Private Securities Litigation Reform Act of 1995), which are based on the expectations, projections and beliefs of company management at the time of pronouncement. Some forward-looking statements may be identified by the use of such terms as "believes," "anticipates," "may," "intends," "plans," "estimates," "projects" and "expects." The company takes no obligation to update or revise any such statements after the date on which they are made. Forward-looking statements are subject to a wide range of risks and uncertainties that can cause actual results to differ materially from anticipated results. These variable factors include, but are not limited to, operating initiatives and acquisitions, general economic conditions, the competitive environment, federal and state laws and regulations (and changing interpretations thereof), reimbursement rates under government and third party healthcare programs and unanticipated expenditures. Accordingly, no assurance can be given as to the future financial condition, cash flow or results of operations of the company or any of its businesses. Further information regarding factors that could cause the company's results to differ from expectations is included in its annual reports.

###

Read the full story at http://www.prweb.com/releases/2009/05/prweb2462804.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. MDS Nordion Opens New Radiopharmaceutical Production Facility in Belgium
2. PRA International Opens Additional Drug Safety Center in Sao Paulo, Brazil
3. Alexian Brothers Medical Center Opens New Patient Tower
4. National Eyewear Chain Visionworks Opens Two New Stores in Orlando Market
5. National Eyewear Chain EyeMasters Opens Tenth Store in Cleveland Market
6. Law Offices of Bruce Egert Opens New Office in Hackensack
7. News media registration opens for ACS National Meeting in Washington, DC, Aug. 16-20
8. Medifast Weight Control Center Opens in Round Rock, TX
9. Research opens up new horizons to the design of customized medicines against breast cancer
10. As Kaiser Permanente Opens a New Hospital Wing, Security Officers Left Behind Without Affordable Healthcare
11. Hospital Opens New $19 Million Neonatal Intensive Care Unit
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CBLPath Opens Manhattan Facility
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Aimed at ... human interest stories, which come courtesy of leaders in the nursing and health care ... from leading advocates and associations—namely Abilene Christian University. , As the nursing industry ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a ... (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the 90 ... their favorite way to cook a hot dog, far outpacing other cooking methods such ...
(Date:5/26/2016)... Atlanta, Georgia (PRWEB) , ... May 26, 2016 ... ... a certificate in intellectual property (IP) to its specialty academic programs. , Answering ... joins the college’s existing certificate programs in health law, and environmental and land ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology: